Stockreport

Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B

Catalyst Biosciences, Inc.  (CBIO) 
Last catalyst biosciences, inc. earnings: 11/7 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: catalystbiosciences.com/investors
PDF Initiation of Phase 2b Trial on Track for Q3 2018 SOUTH SAN FRANCISCO, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinic [Read more]